Nuevas herramientas para el diagnóstico y el tratamiento de la enfermedad de hígado graso no alcohólico y la resistencia a insulina asociada a obesidad

Zusammenfassung

Insulin resistance and altered glucose and lipid metabolism stand out among the main obesity-associated complications. This condition can lead to the development of comorbidities, such as non-alcoholic fatty liver disease (NAFLD) or type 2 diabetes mellitus (DM2), which have common features. NAFLD is the most common liver pathology in Western countries, whose prevalence is continuously growing. This manifestation is mainly defined by the presence of steatosis in more than 5% of hepatocytes and its progression can cause non-alcoholic steatohepatitis (NASH). Although there are well-characterized factors involved in the progression of steatosis to NASH, such as lipotoxicity, oxidative stress and immune system activation, many others are still unknown. Due to the lack of treatment for this disease, it is necessary to deepen the knowledge of new mediators, including microRNAs (miRNAs), and therapeutic approaches, such as gene therapy, to prevent the development and progression of NAFLD...